Policy Areas

• Home
• Policy Areas
• Medical Services

Print

Medical Services

Development FocusMainland Policies and Measures

Healthcare system in Hong Kong is of high standard and served with dedicated healthcare professionals. The Government supports the development of Hong Kong's quality healthcare services in the Greater Bay Area. The Government has also been actively promoting the continual development of Chinese medicine, strengthening the services provision, research and innovation. The planning and development of the first Chinese medicine hospital in Hong Kong is underway. The Government is also actively planning the establishment of the permanent Government Chinese Medicines Testing Institute to develop Hong Kong into an international hub for scientific research on Chinese medicines testing and quality control.

• Under the Mainland and Hong Kong Closer Economic Partnership Arrangement (CEPA), statutory healthcare professionals who are registered to practise in Hong Kong are allowed to provide short-term services in the Mainland.
• The University of Hong Kong-Shenzhen Hospital (HKU-SZ Hospital), wholly invested by the Shenzhen Government and managed by the University of Hong Kong, is a comprehensive public hospital. Since its operation in July 2012, the HKU-SZ Hospital has been providing healthcare services to the public in addition to undertaking research and teaching.
• The Government has launched the Pilot Scheme at the HKU-SZ Hospital in October 2015 to enable eligible Hong Kong elders to use health care vouchers to pay for the fees of outpatient services provided by designated clinics/departments of the HKU-SZ Hospital. The Pilot Scheme has been regularised with effect from 26 June 2019.
• Hong Kong's healthcare system ranked the most efficient healthcare system among the 56 economies covered in a study conducted by Bloomberg in 2018.
• As a facilitation measure for Hong Kong residents working and living in the Greater Bay Area to seek healthcare services, the Central Government issued the work plan for regulatory innovation and development of pharmaceutical and medical device in the Greater Bay Area on 25 November 2020 that the use of Hong Kong-registered drugs and common medical devices are allowed in designated Hong Kong-owned healthcare institutions in the Greater Bay Area. The Government has been maintaining close liaison with the relevant Mainland authorities to discuss the implementation of the Measure at the HKU-SZ Hospital on a trial basis, including establishing a collaborative platform and making agreement on the directory of drugs and medical devices that can be used in designated healthcare institutions in the Greater Bay Area etc. The Guangdong Provincial Medical Products Administration (GDMPA) has commenced the Measure to use the relevant drugs and medical devices at the HKU-SZ Hospital on a trial basis, with a trial period up till 31 July 2021. The Government will continue to work and liaise closely with the GDMPA to implement the Measure, with a view to expanding the directory of drugs and medical devices as soon as possible, and extending the arrangement gradually to cover more designated healthcare institutions in the Greater Bay Area after achieving phased progress under the trial arrangement at the HKU-SZ Hospital.

The University of Hong Kong-Shenzhen Hospital